Results 21 to 30 of about 5,663,878 (222)
Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Endocrine reviews, 2023 Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated aldosterone production that occurs despite suppression of renin and angiotensin II, and that is non-suppressible by volume and sodium loading.
G. Hundemer +5 more
semanticscholar +1 more source
Endocrine journal, 2022 Primary aldosteronism (PA) is associated with higher cardiovascular morbidity and mortality rates than essential hypertension. The Japan Endocrine Society (JES) has developed an updated guideline for PA, based on the evidence, especially from Japan.
M. Naruse +29 more
semanticscholar +1 more source
Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism [PDF]
, 2020 Primary aldosteronism (PA) is the most common form of endocrine hypertension. Agonistic autoantibodies against the angiotensin II type 1 receptor (AT1R-Abs) have been described in transplantation medicine and women with pre-eclampsia and more recently in
Siyuan, Gong +3 more
core +1 more source
Primary aldosteronism: molecular medicine meets public health
Nature Reviews Nephrology, 2023 Primary aldosteronism is the most common single cause of hypertension and is potentially curable when only one adrenal gland is the culprit. The importance of primary aldosteronism to public health derives from its high prevalence but huge under ...
E. Azizan +2 more
semanticscholar +1 more source
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Endocrine reviews, 2023 Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure–matched cases of primary hypertension.
N. Mullen +6 more
semanticscholar +1 more source
Mineralocorticoid receptor signalling in primary aldosteronism.
Journal of Endocrinology, 2023 Primary Aldosteronism, or Conn Syndrome, is the most common endocrine cause of hypertension. It is associated with a higher risk of cardiovascular, metabolic and renal diseases, as well as a lower quality of life than for hypertension due to other causes.
Jun Yang +3 more
semanticscholar +1 more source
Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection.
American Journal of Kidney Diseases, 2023 A clinical condition may be missed due to its higher-than-recognized prevalence or inadequate diagnostic screening. Primary aldosteronism suffers from both of these factors and thus, is woefully underdiagnosed as a cause of hypertension and end-organ ...
Mario Funes Hernandez, Vivek Bhalla
semanticscholar +1 more source
Primary Aldosteronism: State-of-the-Art Review.
American Journal of Hypertension, 2022 We are witnessing a revolution in our understanding of primary aldosteronism. In the past two decades, we have learned that primary aldosteronism is a highly prevalent syndrome that is largely attributable to pathogenic somatic mutations, that ...
A. Vaidya +4 more
semanticscholar +1 more source
Journal of Internal Medicine, 2023 Primary aldosteronism (PA) is a frequent cause of hypertension. Aldosterone excess together with high dietary salt intake aggravates cardiovascular damage, despite guideline‐recommended mineralocorticoid receptor antagonist (MRA) treatment.
Holger Schneider +14 more
semanticscholar +1 more source
Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism [PDF]
, 2020 First described in 1955 by Jerome W. Conn, primary aldosteronism (PA) today is well established as a relevant cause of secondary hypertension and accounts for about 5–10 % of hypertensives.
Heinrich, Daniel A. +4 more
core +1 more source